Sort   by:  
 Page size 
UnknownRisk factors for non-adherence and loss to follow-up in a three-year clinical trial in Botswana.
Not available
S-EPMC3081815 | biostudies-literature
UnknownTuberculosis treatment outcomes among people living with HIV diagnosed using Xpert MTB/RIF versus sputum-smear microscopy in Botswana: a stepped-wedge cluster randomised trial.
Not available
S-EPMC6915885 | biostudies-literature
UnknownHigher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: Implications for diagnostic algorithms using Xpert MTB/RIF assay.
Not available
S-EPMC5741233 | biostudies-literature
UnknownTuberculosis preventive treatment opportunities at antiretroviral therapy initiation and follow-up visits.
Not available
S-EPMC7316437 | biostudies-literature
UnknownPeripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswana.
Not available
S-EPMC5560557 | biostudies-literature
UnknownEffect of tuberculosis screening and retention interventions on early antiretroviral therapy mortality in Botswana: a stepped-wedge cluster randomized trial.
Not available
S-EPMC7011529 | biostudies-literature
UnknownThe effect of sputum quality and volume on the yield of bacteriologically-confirmed TB by Xpert MTB/RIF and smear.
Not available
S-EPMC6711687 | biostudies-literature
UnknownDerivation and external validation of a risk score for predicting HIV-associated tuberculosis to support case finding and preventive therapy scale-up: A cohort study.
Not available
S-EPMC8454974 | biostudies-literature
UnknownRisk scores for predicting early antiretroviral therapy mortality in sub-Saharan Africa to inform who needs intensification of care: a derivation and external validation cohort study.
Not available
S-EPMC7650165 | biostudies-literature
UnknownHigh-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Not available
S-EPMC4233406 | biostudies-literature
Sort   by:  
 Page size